Zacks: Analysts Expect Cerus Co. (NASDAQ:CERS) to Post -$0.11 EPS

Share on StockTwits

Equities analysts predict that Cerus Co. (NASDAQ:CERS) will post earnings of ($0.11) per share for the current quarter, according to Zacks. Two analysts have made estimates for Cerus’ earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.12). Cerus also reported earnings of ($0.11) per share in the same quarter last year. The business is expected to announce its next quarterly earnings report on Thursday, November 7th.

On average, analysts expect that Cerus will report full year earnings of ($0.48) per share for the current financial year, with EPS estimates ranging from ($0.50) to ($0.43). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.46) to ($0.25). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Cerus.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01). The company had revenue of $18.20 million during the quarter, compared to analysts’ expectations of $17.55 million. Cerus had a negative return on equity of 85.73% and a negative net margin of 98.69%. Cerus’s revenue for the quarter was up 18.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.10) EPS.

A number of equities analysts recently issued reports on CERS shares. BidaskClub cut Cerus from a “hold” rating to a “sell” rating in a report on Friday, October 4th. Stifel Nicolaus started coverage on Cerus in a report on Tuesday, August 27th. They set a “buy” rating and a $7.00 price objective for the company. Zacks Investment Research upgraded Cerus from a “sell” rating to a “hold” rating in a report on Monday, October 7th. ValuEngine upgraded Cerus from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Finally, Stephens started coverage on Cerus in a report on Thursday, August 22nd. They set an “overweight” rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Cerus has an average rating of “Buy” and a consensus price target of $7.63.

In other Cerus news, SVP Carol Moore sold 30,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $5.33, for a total value of $159,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Timothy B. Anderson sold 18,795 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $5.40, for a total value of $101,493.00. Following the completion of the sale, the director now owns 177,649 shares of the company’s stock, valued at $959,304.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 74,903 shares of company stock valued at $394,513. 7.26% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the business. Primecap Management Co. CA lifted its holdings in shares of Cerus by 4.6% in the 2nd quarter. Primecap Management Co. CA now owns 11,300,000 shares of the biotechnology company’s stock worth $63,506,000 after buying an additional 500,000 shares during the period. BlackRock Inc. lifted its holdings in shares of Cerus by 2.0% in the 2nd quarter. BlackRock Inc. now owns 10,983,209 shares of the biotechnology company’s stock worth $61,727,000 after buying an additional 211,548 shares during the period. ARK Investment Management LLC lifted its holdings in shares of Cerus by 11.2% in the 2nd quarter. ARK Investment Management LLC now owns 8,493,022 shares of the biotechnology company’s stock worth $47,731,000 after buying an additional 853,589 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Cerus by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 7,006,902 shares of the biotechnology company’s stock worth $39,378,000 after buying an additional 23,356 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Cerus by 444.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,049,385 shares of the biotechnology company’s stock worth $28,378,000 after buying an additional 4,121,845 shares during the period. Institutional investors and hedge funds own 72.93% of the company’s stock.

Shares of Cerus stock traded up $0.02 on Monday, reaching $4.49. The company had a trading volume of 589,108 shares, compared to its average volume of 860,230. The firm’s 50-day moving average price is $4.91 and its two-hundred day moving average price is $5.33. Cerus has a 1 year low of $4.29 and a 1 year high of $6.88. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.67 and a quick ratio of 2.33. The firm has a market cap of $627.23 million, a price-to-earnings ratio of -10.19 and a beta of 1.64.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Story: How does inflation affect different investments?

Get a free copy of the Zacks research report on Cerus (CERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.